Last Updated: June 18, 2026

Litigation Details for SK nexilis Co., Ltd. v. Solus Advanced Materials Co., Ltd. (E.D. Tex. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in SK nexilis Co., Ltd. v. Solus Advanced Materials Co., Ltd.
The small molecule drugs covered by the patent cited in this case are ⤷  Start Trial and ⤷  Start Trial .

Litigation summary and analysis for: SK nexilis Co., Ltd. v. Solus Advanced Materials Co., Ltd. (E.D. Tex. 2023)

Last updated: June 18, 2026

SK nexilis Co., Ltd. v. Solus Advanced Materials Co., Ltd. (2:23-cv-00539): Litigation Summary, Patent Claims, and Likely IP Exposure

Executive summary: The docket number 2:23-cv-00539 reflects a federal patent infringement action by SK nexilis Co., Ltd. against Solus Advanced Materials Co., Ltd. The case posture, asserted patents, claim scope, venue details, and any settlement or dispositive rulings are not provided in the input, so a complete litigation summary and infringement/patent-estate analysis cannot be produced from available information.

What does SK nexilis Co., Ltd. v. Solus Advanced Materials Co., Ltd. (2:23-cv-00539) allege?

Case allegations: Not provided. A litigation summary requires the complaint’s core elements: (1) asserted patents and their numbers, (2) accused products and how they map to claim limitations, (3) counts asserted (direct infringement, inducement, willfulness), and (4) requested remedies.

Which patents are asserted in 2:23-cv-00539

Not provided.

Which products are accused in 2:23-cv-00539

Not provided.

What infringement theories are pleaded

Not provided.

What patents protect the technology at issue in SK nexilis v. Solus?

Patent protection analysis: Not possible without identifying (a) the asserted patents in the case or (b) the technology class and jurisdiction-specific families tied to the parties.

What is the relevant patent estate (grants, continuations, and key claim scope)

Not provided.

How broad are the asserted claims (independent claim structure and common limitations)

Not provided.

What is the procedural status of 2:23-cv-00539 (motions, hearings, rulings)?

Procedural posture: Not provided. A litigation summary requires the docket timeline: complaint filing date, scheduling order, motion-to-dismiss outcomes, claim construction schedule, summary judgment motions, trial date status, and any orders on discovery.

When was the complaint filed and what deadlines were set

Not provided.

Has the court issued claim construction (Markman) in 2:23-cv-00539

Not provided.

Have there been dispositive motions (dismissal, summary judgment)

Not provided.

Has the case settled or gone to trial

Not provided.

How strong is SK nexilis’s case based on the pleadings and infringement mapping?

Strength assessment: Not possible without the asserted claims, claim charts, and the court’s substantive rulings (if any).

What are the likely invalidity targets (anticipation, obviousness, indefiniteness, written description)

Not provided.

What are the likely non-infringement defenses

Not provided.

Willfulness and enhanced damages exposure

Not provided.

What patent defenses or counters does Solus Advanced Materials raise in 2:23-cv-00539?

Defense set: Not provided.

Claim invalidity under 35 U.S.C. §§ 102, 103, 112

Not provided.

Non-infringement and design-around arguments

Not provided.

Jurisdiction, venue, and standing challenges

Not provided.

Does SK nexilis seek injunctive relief or damages in 2:23-cv-00539?

Remedies: Not provided. A remedies analysis requires the complaint’s demand for relief and any subsequent briefing on injunction, accounting of profits, or damages theories.

Damages model (lost profits vs. reasonable royalty vs. disgorgement)

Not provided.

Requested injunction scope

Not provided.

What comparable IP litigation or licensing context exists between SK nexilis and Solus?

Prior/pending matters: Not provided. A business-useful litigation analysis requires identification of related cases, settlements, prior claim charts, or cross-licenses.

Any related counterpart litigation in other districts

Not provided.

Any PTAB activity (IPR/PGR) tied to the asserted patents

Not provided.

Key Takeaways

Not available: The input contains only the case caption and docket number. No asserted patents, claims, accused products, procedural dates, or court orders are provided, so a litigation summary and patent exposure analysis cannot be generated without fabricating facts.

FAQs

  1. What is the court and judge for 2:23-cv-00539? Not provided.
  2. Which patents are asserted by SK nexilis in the complaint? Not provided.
  3. What is the current stage of discovery or claim construction? Not provided.
  4. Did Solus file post-complaint motions or seek dismissal? Not provided.
  5. Has there been any settlement or consent judgment in 2:23-cv-00539? Not provided.

References

  1. Not provided in the input.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.